Navigation Links
InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
Date:9/13/2010

  • 10:00 a.m. -- Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (Ron du Bois, M.D.)

  • About Pirfenidone

    InterMune has submitted a Marketing Authorization Application (MAA) seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, which was validated by the European Medicines Agency (EMA) effective March 24, 2010. Validation of the MAA by the EMA indicates that the application is complete and that the review process has begun.

    IPF is a rare and fatal lung disease that affects approximately 200,000 people in the United States and Europe combined. If approved by the EMA, pirfenidone would be the first medication to be made available to IPF patients in the European Union. Pirfenidone has been granted Orphan Drug designation in Europe.

    Preclinical and in-vitro evidence has shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating pirfenidone for the treatment of IPF, known as the CAPACITY trials. Prior to the CAPACITY results, Shionogi & Co. Ltd (Shionogi) had presented data from a Phase 3 study conducted in Japan which demonstrated that pirfenidone reduced the decline in lung function and improved progression-free survival in patients with IPF. In this clinical study, pirfenidone was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

    About InterMune

    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. InterMune to Release Second Quarter Financial Results on July 27
    2. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
    3. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
    4. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
    5. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
    6. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
    7. InterMune to Present at Deutsche Bank Biotech Confab
    8. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
    9. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
    10. InterMune to Present at JMP Securities Conference
    11. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
    (Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
    (Date:12/15/2014)... 2014 Research and Markets ( ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... applications made a lot of progress in the ... are now accepted in high-reliability environments, and are ...
    Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
    ... BEIJING , July 7 ... the "Company") (NYSE: CCM ), operator of,the largest ... ,today announced that it has filed its annual report for ... 20-F with the U.S. Securities and Exchange,Commission on June ...
    ... , SAN FRANCISCO , July 7 ... (Nasdaq: NLTX ), a biopharmaceutical company focused on ... announced that it has completed the dosing of the ... II study of CD-NP in patients with acute decompensated ...
    Cached Medicine Technology:Concord Medical Files 2009 Annual Report on Form 20-F 2Nile Therapeutics Completes Dosing of Phase II Study 2Nile Therapeutics Completes Dosing of Phase II Study 3
    (Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
    (Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
    (Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
    (Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
    (Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
    Breaking Medicine News(10 mins):Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
    ... first astronaut, involved in a 25 million dollar space ... on the growth of cancer cells in outer space, ... conduct research on cells, bacteria and the crystallisation of ... Molecule Medical Institute at the National University of Malaysia. ...
    ... College London have found that injections of stem cells ... of children with brittle bone disease , osteogenesis imperfecta ... foetuses by DNA testing or ultrasound, disrupts collagen production, ... the condition suffer fractures while in the womb, and ...
    ... on Wednesday proposed uprooting excess vineyards and launching an ... strategy aimed at soaking up glut and countering New ... that the European Union's annual wine budget of 1.3 ... "a very inefficient way" despite huge challenges facing the ...
    ... cat allergen is associated with greater bronchial responsiveness (BR) ... they are not specifically allergic to cats. This suggests ... allergic individuals, regardless of their specific allergies. ... lead author of the study. We presupposed that we ...
    ... Makes a Lot of Noise has had to turn it ... effect this week . But where there are 8,000,000 New ... of Environmental Protection has a phone line, 311, for quality-of-life ... callers say, is distracting, annoying, shrill, dull or rattling -- ...
    ... after tests on three dead swans in the northeast confirmed an ... fatal to humans. ,"France is not threatened by ... moment, a human contamination from the H5N1 virus," Health Minister Roselyne ... as the great flu epidemic that followed the war of 1914, ...
    Cached Medicine News:Health News:EU Aims to Shake Up Wine Industry With Root-and-branch Reform 2Health News:Cat Exposure Increases Bronchial Responsiveness 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 3Health News:France Steps Up Vigilance After Bird Flu Outbreak 2
    ... The Thumper Board provides optimum head hyperextension, open ... intubation easier. Placed at strategic locations throughout ... CPR to be started immediately, and easy conversion ... patient application can be done in less than ...
    The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
    ... CryoCath has developed a minimally ... reentrant tachycardia. It delivers a very ... site confirmation, pinpoint site precision, minimal ... thrombus and stenosis., ,Freezor is a ...
    The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
    Medicine Products: